Transcriptomic analysis of human castration-resistant prostate cancer: Insights into novel therapeutic strategies

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Prostate cancer is a leading cause of male cancer deaths globally.
• Androgen deprivation therapy (ADT) is standard for advanced prostate cancer but often leads to castration-resistant prostate cancer (CRPC).
• CRPC presents a major therapeutic challenge due to disease progression and treatment resistance.

Purpose of the Study:

• To investigate the genetic drivers of CRPC using transcriptomic analysis.
• To identify novel therapeutic targets for CRPC.
• To explore potential drug combinations for overcoming resistance.

Main Methods:

• RNA sequencing (RNA-seq) and bioinformatics tools were used to analyze gene expression.
• Differentially expressed genes (DEGs) related to tumor progression, cytoskeletal dynamics, and immune modulation were identified.
• Functional enrichment analysis and molecular docking studies were performed.

Main Results:

• Key DEGs including COL3A1, MYH4, FN1, ACTN1, and CALR were identified.
• Significant pathways involved in CRPC include actin-myosin filament sliding, calcium signaling, androgen receptor signaling, immune evasion, and metabolism.
• Molecular docking showed strong binding between CRPC genes (ABCC4, FOLH1) and potential ligands (flutamide, N-acetyl glucosamine).

Conclusions:

• Transcriptomic analysis provides insights into the molecular mechanisms of CRPC progression.
• Identified genes and pathways offer potential targets for novel therapies.
• Drug-ligand interactions suggest strategies to overcome therapeutic resistance in CRPC.